Imagine trying a few different keys to open a door without knowing which one fits, wasting time and effort. This project creates a biological 'key-checker' using a blood test to see if a specific expensive medicine will actually work for a patient. It uses a computer program to read chemical marks on DNA, acting like a GPS to guide doctors to the most effective treatment immediately.
Doctors currently cannot predict which expensive biologic drug will work for a Crohn's patient, leading to a failure rate of over 60%. This results in avoidable disease complications and wasted healthcare spending.
A predictive algorithm-supported epigenetic biomarker assay and a rapid, targeted methylation assay for peripheral blood.
If you are a diagnostics company dealing with a lack of high-accuracy predictive tests for inflammatory diseases — this project developed a targeted methylation assay that predicts treatment response with up to 93% accuracy. This allows you to launch a market-ready kit for personalized medicine in Crohn's disease.
If you are a pharma company dealing with high drug failure rates where less than 40% of patients respond to a therapy — this project developed a validated biomarker assay that identifies responders. This can optimize clinical trial recruitment and improve the perceived efficacy of your biologicals.
If you are a clinic dealing with high healthcare costs and patient complications due to trial-and-error prescribing — this project developed a rapid diagnostic tool to select the most suitable therapy. This reduces wasted spending on ineffective drugs and improves patient quality of life.
Based on available project data, specific pricing is not mentioned, but the project explicitly assesses efficiency and cost-effectiveness to ensure the kit is marketable.
Yes, the project aims to develop a rapid, market-ready targeted methylation assay and includes 7 industry partners to ensure the tool meets regulatory standards for clinical approval.
Based on available project data, the project is developing a marketable epigenetic kit, though specific licensing terms are not detailed in the summary.
The assay is being validated through a unique prospective randomized clinical trial for Crohn's disease and guided by regulatory experts.
The project runs from 2023-01-01 to 2026-12-31, aiming to deliver a market-ready assay by the end of the period.
The consortium is highly commercially oriented, featuring 18 partners across 9 countries. With a 39% industry ratio (7 companies, including 5 SMEs), the project is structured for translation rather than just basic research. The mix of clinical experts, DNA diagnostics specialists, and patient organizations suggests a strong pipeline from lab validation to clinical trial and eventual market entry.
Contact Stichting Amsterdam UMC regarding the METHYLOMIC epigenetic kit
Contact us to connect with the METHYLOMIC consortium for licensing opportunities.
